{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:04:41Z","timestamp":1792098281752,"version":"4.4.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1681\/asn.2014070640","type":"journal-article","created":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T01:44:41Z","timestamp":1427247881000},"page":"2545-2558","source":"Crossref","is-referenced-by-count":348,"title":["Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy"],"prefix":"10.1681","volume":"26","author":[{"given":"Piero","family":"Ruggenenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Debiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Chianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothee","family":"Pell\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Gaspari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Suardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Orisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Benigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-27-20230208","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy.","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"R2-27-20230208","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2215\/CJN.05231008","article-title":"Rituximab therapy for membranous nephropathy: A systematic review.","volume":"4","author":"Bomback","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R3-27-20230208","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000327611","article-title":"Efficacy and safety of rituximab second-line therapy for membranous nephropathy: A prospective, matched-cohort study.","volume":"33","author":"Cravedi","year":"2011","journal-title":"Am J Nephrol"},{"key":"R4-27-20230208","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2215\/CJN.06041108","article-title":"Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients.","volume":"4","author":"Segarra","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R5-27-20230208","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy.","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R6-27-20230208","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJMe0903343","article-title":"Human idiopathic membranous nephropathy--a mystery solved?","volume":"361","author":"Glassock","year":"2009","journal-title":"N Engl J Med"},{"key":"R7-27-20230208","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1517\/14656566.8.18.3159","article-title":"Latest treatment strategies for membranous nephropathy.","volume":"8","author":"Ruggenenti","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R8-27-20230208","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies.","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med"},{"key":"R9-27-20230208","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"R10-27-20230208","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1681\/ASN.2011060610","article-title":"Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy.","volume":"22","author":"Cravedi","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R11-27-20230208","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med"},{"key":"R12-27-20230208","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2215\/CJN.05310513","article-title":"HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy.","volume":"9","author":"Bullich","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-27-20230208","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1681\/ASN.2012080771","article-title":"Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy.","volume":"24","author":"Lv","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R14-27-20230208","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00281-014-0423-y","article-title":"Immunopathogenesis of membranous nephropathy: An update.","volume":"36","author":"Debiec","year":"2014","journal-title":"Semin Immunopathol"},{"key":"R15-27-20230208","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R16-27-20230208","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"key":"R17-27-20230208","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.","volume":"25","author":"Hoxha","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R18-27-20230208","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.","volume":"23","author":"Hofstra","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R19-27-20230208","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R20-27-20230208","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R21-27-20230208","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1681\/ASN.V9122272","article-title":"Mycophenolate mofetil prevents the induction of active Heymann nephritis: Association with Th2 cytokine inhibition.","volume":"9","author":"Penny","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"R22-27-20230208","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/00001813-200211002-00007","article-title":"Aggressive lymphoma: Improving treatment outcome with rituximab.","volume":"13","author":"Coiffier","year":"2002","journal-title":"Anticancer Drugs"},{"key":"R23-27-20230208","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R24-27-20230208","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: Relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R25-27-20230208","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar3770","article-title":"Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity.","volume":"14","author":"Teng","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R26-27-20230208","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: A 2-year study.","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R28-27-20230208","doi-asserted-by":"crossref","first-page":"c253","DOI":"10.1159\/000320194","article-title":"Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy.","volume":"117","author":"Kim","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"R29-27-20230208","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1160\/TH07-12-0753","article-title":"Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.","volume":"101","author":"Bresin","year":"2009","journal-title":"Thromb Haemost"},{"key":"R31-27-20230208","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/sim.3864","article-title":"Modelling continuous exposures with a \u2018spike\u2019 at zero: A new procedure based on fractional polynomials.","volume":"29","author":"Royston","year":"2010","journal-title":"Stat Med"},{"key":"R32-27-20230208","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/bimj.201100263","article-title":"Analysing covariates with spike at zero: A modified FP procedure and conceptual issues.","volume":"54","author":"Becher","year":"2012","journal-title":"Biom J"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201510000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:26:08Z","timestamp":1786130768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201510000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2014070640","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}